Squamous Cell Carcinoma 4+ EGFR Carboplatin Cetuximab Safely or Bevacizumab
Description: Roy S. Herbst, MD, PhD of Yale Cancer Center discusses squamous cell carcinoma 4+ EGFR and giving carboplatin cetuximab safely or bevacizumab. In the November 28th issue of Lungs and Oncology, data shows that carboplatin cetuximab can be given safely and bevacizumab can also be used when necessary. Patients with squamous cell disease who have high copy number, 4+ EGFR gene, seem to benefit more on this for the overall survival. This is a pre-specified subset of the trial, which could be a biomarker that can be used for future studies. Right now, EGFR antibodies is used either with chemotherapy or with immunotherapy or other combination on lung cancer. This will be another potential tool that can be used to fight against this disease.